(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp.(CHRO) to combine Ligand's wholly owned subsidiaries, Pelthos ...

JUPITER, Fla. and FREEHOLD, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (“Ligand”) (Nasdaq: LGND) and Channel Therapeutics ...

Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin ...

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo ...